Hematologic complications of heparin-induced thrombocytopenia

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 2 SUPPL. 1, 1999, Pages 17-21

  Raible, Michele D ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibody; Heparin; Platelet factor 4; Thrombocytopenia; Thrombosis

Indexed keywords

DRUG ANTIBODY; HEPARIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; THROMBOCYTE FACTOR 4;

ANTICOAGULATION; ANTIGEN ANTIBODY REACTION; ARTERY THROMBOSIS; CONFERENCE PAPER; HEMOSTASIS; HUMAN; IMMUNOPATHOGENESIS; LUNG EMBOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ANTICOAGULANTS; HEMATOLOGIC DISEASES; HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 0032917827     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Shulman NR. A mechanism of cell destruction in individuals sensitized to foreign antigens and its implications in auto-immunity. Ann Intern Med 1964;60:506-521
2. Natelson EA, Lynch EC, Alfrey CP, Gross JB. Heparin-induced thrombocytopenia. Ann Intern Med 1969;71:1121-1125
3. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg 1958;76:219-227
4. Fratantoni JC, Pollet R, Gralnick HR. Heparin-induced thrombocytopenia: Confirmation of diagnosis with in vitro methods. Blood 1975;45:395-401
5. Rhodes GR, Dixon RH, Silver D. Heparin-induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973;136:409-416
6. Bell WR, Tomasulo PA, Alving BM, Duffy TP. Thrombocytopenia occurring during the adminstration of heparin. Ann Intern Med 1976;85:155-160
7. Ansell J, Deykin D. Heparin-induced thrombocytopenia and recurrent thromboembolism. Am J Hematol 1980;8:325-332
8. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemostas 1995;21:106-116
9. Messmore HL, Griffin B, Koza M, et al. Interaction of heparinoids with platelets: Comparison with heparin and low molecular weight heparins. Semin Thromb Hemostas 1991;17(Suppl 1):57-59
10. Messmore HL, Griffin B, Fareed J, Coyne E, Seghatchian J. In vitro studies of the interaction of heparin, low-molecular-weight heparin and heparinoids with platelets. Ann NY Acad Sci 1989;556:217-232
11. Sobel M, Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res 1988;50: 815-826
12. Horne MK, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol 1990;74:306-312
13. Holmer E, Lindahl U, Bäckström G, et al. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980;18:861-869
14. Horne MK, Chao ES. Heparin binding to resting and activated platelets. Blood 1989;74:238-243
15. Brace LD, Fareed J. An objective assessment of the interaction of heparin and its fractions with human platelets. Semin Thromb Hemostas 1985;11:190-198
16. Schmitz-Huebner U, Balleisen L, Asbeck F, van de Loo J. In vivo studies on the inhibition of coagulation by fractionated heparin and by a heparin analogue. Thromb Haemostas 1981;46:612-616
17. Bell WR. Heparin-associated thrombocytopenia and thrombosis. J Lab Clin Med 1988;111:600-605
18. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: A critical review and pooled analysis. Am J Med Sci 1993;305:208-215
19. Walenga JM, Koza MJ, Lewis BE, Pifarré R. Relative heparin-induced thrombocytopenic potential of low-molecular-weight heparins and new antithrombotic agents. Clin Appl Thromb/ Hemostas 1996;2(Suppl. 1):S21-S27
20. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984;100:535-540
21. Messmore HL, Nand S, Godwin J. Heparin-induced thrombocytopenia and platelet activation in cardiovascular surgery. In: Pifarré R, ed. Anticoagulation, Hemostasis, and Blood Preservation in Cardiovascular Surgery. Philadelphia: Hanley & Belfus, 1993:185-199
22. Boshkov LK, Warkentin TE, Hayward CPM, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies. Br J Haematol 1993;84:322-328
23. Wallis DE, Lewis BE, PifarréR, Scanlon PJ. Active surveillance for heparin-induced thrombocytopenia and thromboembolism. Chest 1994;106:120S(Abst)
24. Towne JB, Bernhard VM, Hussey C, Garancis JC. White clot syndrome. Arch Surg 1979;114:372-377
25. Hach-Wunderle V, Kainer K, Salzmann G, Muller-Berghaus G, Pötzsch B. Heparin-related thrombosis despite normal platelet counts in vascular surgery. Am J Surg 1997;173:117-119
26. Kelton JG, Warkentin TE. Diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995;104:611-613
27. Walenga JM, Jeske WP, Fasanella AR, Wood JJ, Bakhos M. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemostas 1999;25(Suppl 1):43-50
28. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet 1982;2:1246-1249
29. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocyopenia: Laboratory studies. Blood 1988;72:925-930
30. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989;73:235-240
31. Chong BH, Pilgrim RL, Cooley MA, Chesterman CN. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 1993;81:988-993
32. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemostas 1992;68:95-96 (Letter)
33. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-3239
34. Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemostas 1994;71:247-251
35. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-88
36. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996;88:410-416
37. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemostas 1995; 73:21-28
38. Horne MK, Alkins BR. Platelet binding of IgG from patients with heparin-induced thrombocytopenia. J Lab Clin Med 1996;127: 435-442
39. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low-molecular-weight heparin and heparinoid. Thromb Haemostas 1998;80:292-297
40. Amiral J, Wolf M, Fischer AM, et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996;92: 954-959
41. Visentin GP, Malik MI, Menden K, Aster RH. A prospective study of the formation of antibodies reactive with heparin: PF4 complexes in patients treated with heparin. Blood 1994; 84(Suppl 1):80(Abst)
42. Aster RH. Heparin-induced thrombocytopenia: Understanding improves but questions remain. J Lab Clin Med 1996;127: 418-419
43. Horne MK, Hutchison KJ. Simultaneous binding of heparin and platelet factor-4 to platelets: Further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 1998;58:24-30
44. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haemotol 1996;95:161-167
45. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin platelet factor 4. Blood 1998;91:916-922
46. Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998;92:3250-3259
47. Kwaan HC, Sakurai S. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia. Semin Thromb Hemostas 1999;25(Suppl 1):23-28
48. 131) gene in patients with heparin-induced thrombocytopenia. J Lab Clin Med 1997;130:278-284
49. 131 polymorphism, subclass-specific IgG antiheparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 1997;89:370-375
50. Burgess JK, Lindeman R, Chesterman CN, Chong BH. Single amino acid mutation of Fcγ receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 1995;91:761-766
51. Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997;54:196-201
52. Lee DH, Warkentin TE, Denomme GA, Lagrotteria DD, Kelton JG. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia. Thromb Haemostas 1998;79:50-53
53. Barradas MA, Mikhailidis DP, Epemolu O, et al. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low-molecular-weight heparin fraction (CY 222). Br J Haematol 1987;67:451-457
54. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: The antibody is not heparin-specific. Thromb Haemostas 1992;67:545-549
55. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;332:1374-1376
56. Goad KE, Horne MK, Gralnick HR. Pentosan-induced thrombocytopenia: Support for an immune complex mechanism. Br J Haematol 1994;88:803-808
57. Ramakrishna R, Manoharan A, Kwan YL, Kyle PW. Heparin-induced thrombocytopenia: Cross-reactivity between standard heparin, low-molecular-weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran). Br J Haematol 1995;91:736-738
58. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335
59. Raible MD, Wolf H, Leya F, et al. Post-PTCA generation of Hep-PF4 antibodies is associated with previous exposure to unfractionated heparin. Studies with the chronic administration of a LMWH. Blood 1995;86(Suppl 1):551(Abst)
60. Amiral J, Peynaud-Debayle E, Wolf M, et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996;52:90-95